文献速递骨软组织肉瘤与黑色素瘤

局部软组织肉瘤患者接受新辅助放化疗或放疗后的病理完全缓解与临床结局:NRG/RTOG 9514和0630非随机临床试验

Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials.
PubMed 文献 · JAMA Oncol · 2023-01-01

该辅助分析纳入RTOG 0630(n=79)和RTOG 9514(n=64)两项多机构非随机2期试验的143例局部软组织肉瘤患者,评估病理完全缓解(pCR)与生存结局的关系。9514试验接受放化疗,0630试验接受术前图像引导放疗。pCR与总生存(P=0.01)和无病生存(HR 4.91,95%CI 1.51-15.93,P=0.008)改善相关。

要点

  • RTOG 9514和0630两项非随机2期试验中,pCR率分别为27.5%(14/51)和19.4%(14/72)。
  • pCR患者5年总生存为100%,低于pCR者在9514和0630试验分别为76.5%和56.4%。
  • pCR与总生存改善(P=0.01)和无病生存改善(HR 4.91,95%CI 1.51-15.93,P=0.008)相关。

核心结论

  • 该两项非随机临床试验的辅助分析发现,pCR与软组织肉瘤患者生存改善相关,应作为未来研究的临床结局预后因素。

研究设计与样本

  • RTOG已完成2项多机构非随机2期临床试验,纳入局部软组织肉瘤患者。
  • 本辅助分析纳入RTOG 0630(n=79)和RTOG 9514(n=64)共143例合格患者分析pCR,其中0630的79例评估长期结局。
  • 9514试验患者接受放化疗交错治疗,0630试验患者接受术前单纯放疗。
  • 分析时间为2016年12月14日至2017年4月13日。

主要发现

  • 总体42例(53.2%)为男性,68例(86.1%)为白人,平均(SD)年龄59.6(14.5)岁。
  • RTOG 0630中位随访6.0年,自初次报告以来新增1例野内复发和1例远处失败。
  • 123例可评估pCR:9514试验51例中14例(27.5%)达pCR,0630试验72例中14例(19.4%)达pCR。
  • 5年总生存:pCR患者为100%,低于pCR者在9514试验为76.5%(95%CI 62.3%-90.8%),在0630试验为56.4%(95%CI 43.3%-69.5%)。
  • 5年局部失败率:pCR患者为0%,低于pCR者在9514试验为11.7%(95%CI 3.6%-25.1%),在0630试验为9.1%(95%CI 3.3%-18.5%)。

临床怎么用

  • 作者认为pCR应作为未来研究中软组织肉瘤临床结局的预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pathologic complete response (pCR) may be associated with prognosis in patients with soft tissue sarcoma (STS). OBJECTIVE: We sought to determine the prognostic significance of pCR on survival outcomes in STS for patients receiving neoadjuvant chemoradiotherapy (CT-RT) (Radiation Therapy Oncology Group [RTOG] 9514) or preoperative image-guided radiotherapy alone (RT, RTOG 0630) and provide a long-term update of RTOG 0630. DESIGN, SETTING, AND PARTICIPANTS: RTOG has completed 2 multi-institutional, nonrandomized phase 2 clinical trials for patients with localized STS. One hundred forty-three eligible patients from RTOG 0630 (n = 79) and RTOG 9514 (n = 64) were included in this ancillary analysis of pCR and 79 patients from RTOG 0630 were evaluated for long-term outcomes. INTERVENTION: Patients in trial 9514 received CT interdigitated with RT, whereas those in trial 0630 received preoperative RT alone. MAIN OUTCOMES AND MEASURES: Overall and disease-free survival (OS and DFS) rates were estimated by the Kaplan-Meier method. Hazard ratios (HRs) and P values were estimated by multivariable Cox model stratified by study, where possible; otherwise, P values were calculated by stratified log-rank test. Analysis took place between December 14, 2016, to April 13, 2017. RESULTS: Overall there were 42 (53.2%) men; 68 (86.1%) were white; with a mean (SD) age of 59.6 (14.5) years. For RTOG 0630, at median follow-up of 6.0 years, there was 1 new in-field recurrence and 1 new distant failure since the initial report. From both studies, 123 patients were evaluable for pCR: 14 of 51 (27.5%) in trial 9514 and 14 of 72 (19.4%) in trial 0630 had pCR. Five-year OS was 100% for patients with pCR vs 76.5% (95% CI, 62.3%-90.8%) and 56.4% (95% CI, 43.3%-69.5%) for patients with less than pCR in trials 9514 and 0630, respectively. Overall, pCR was associated with improved OS (P = .01) and DFS (HR, 4.91; 95% CI, 1.51-15.93; P = .008) relative to less than pCR. Five-year local failure rate was 0% in patients with pCR vs 11.7% (95% CI, 3.6%-25.1%) and 9.1% (95% CI, 3.3%-18.5%) for patients with less than pCR in 9514 and 0630, respectively. Histologic types other than leiomyosarcoma, liposarcoma, and myxofibrosarcoma were associated with worse OS (HR, 2.24; 95% CI, 1.12-4.45). CONCLUSIONS AND RELEVANCE: This ancillary analysis of 2 nonrandomized clinical trials found that pCR was associated with improved survival in patients with STS and should be considered as a prognostic factor of clinical outcomes for future studies. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: RTOG 0630 (NCT00589121); RTOG 9514 (NCT00002791).

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wang D, Harris J, Kraybill WG, et al. Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. JAMA Oncol. 2023. PMID: 36995690. doi:10.1001/jamaoncol.2023.0042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。